Just blogged about a suggestion for a revised Body Mass Index formula on the BMJ Diabetes Blog.
"Offer tamoxifen or raloxifene for 5 years to post-menopausal women at high risk of breast cancer unless they have a past history of thromboembolic disease or endometrial cancer."The debate about genetic testing is discussed in the evidence review. There are three genes known to cause susceptibility BRCA1 BRCA2 and TP53 but they cause a minority of cases (5% or so). NICE favour family history over widespread genetic testing but I just wonder what the future will bring? If better genetic risks are identified then the complex computer algorithms and detailed family history checking to quantify risk might give away to more objective test.